Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-05-16 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
2022年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of the company 海思科医药集团股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the 2022 financial report, annual report, board work report, profit distribution plan, and other governance matters. The document is not the full annual report or financial statements but rather the official voting results and decisions made at the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is 4196 characters, which is consistent with a detailed voting results announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2023-05-16 Chinese
关于润能特殊医学用途全营养配方食品获得特殊医学用途配方食品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company Haishike Pharmaceutical Group Co., Ltd. regarding the receipt of a registration certificate for a special medical purpose nutritional formula food product. It includes details about the product, registration number, validity, and risk warnings. The document is short (880 characters) and serves as an official notification about a regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-05-16 Chinese
北京市中伦（深圳）律师事务所关于海思科医药集团股份有限公司2022年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of the company. It discusses the procedures for convening and holding the AGM, the qualifications of the convener and attendees, the voting procedures, and the voting results for various proposals including the 2022 financial report, annual report, board work report, auditor appointment, profit distribution plan, remuneration plan, supervisory board report, and shareholder return plan. The document does not contain the actual financial reports or detailed financial data but rather certifies the legality and validity of the AGM process and voting results. The document length is 3730 characters, which is relatively short and consistent with a legal opinion or voting results announcement rather than a full report. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-16 Chinese
关于获得利鲁唑口溶膜上市许可申请受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving an acceptance notice from the National Medical Products Administration (国家药品监督管理局) for a drug marketing authorization application. It describes the drug, its background, and risks, but does not contain financial statements, management discussion, or detailed financial data. The document length is short (1401 characters) and it is an announcement of a regulatory acceptance notice rather than a financial or management report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is a regulatory announcement related to drug approval status, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-05-10 Chinese
关于控股股东部分股份质押展期及解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from a company regarding the pledge extension and release of shares held by a controlling shareholder. It details the number of shares pledged, the pledge period, and the release of pledged shares. There is no financial statement, earnings data, or management discussion. The content focuses on share pledge and release information, which is related to shareholding and capital structure changes but specifically about pledged shares by a major shareholder. This fits best under the category of Major Shareholding Notification (MRQ), as it involves significant share ownership and pledge status updates by a controlling shareholder.
2023-05-08 Chinese
关于部分控股股东及其部分一致行动人减持公司股份合计超过1%的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding the reduction of shareholdings by certain controlling shareholders and their concerted actors, detailing the number of shares sold, dates, and percentages of total share capital. It includes specific shareholder names, transaction methods, and compliance statements. There is no financial performance data, earnings information, or management discussion. The content focuses on changes in major shareholdings exceeding 1%, which aligns with notifications about significant share ownership changes. Therefore, this document fits the category of Major Shareholding Notification (MRQ). The document length is 3312 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2023-05-03 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.